Results 41 to 50 of about 5,348,587 (297)

THE PROGNOSTIC ROLE OF EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION IN COMPLETELY RESECTED AMPULLARY ADENOCARCINOMA

, 2023
The aim of this study is to make a differential diagnosis and prognosis of the amp-ullary adenocarcinoma subtypes. We also investigated the role of prognostic mark-ers PD-1 and PD-L1, and epidermal growth factor receptor (EGFR). Local or locally advanced
Safiye Aktas, Somall, Isil, Salman, Tarik, Tarık Salman, Fatma Husniye Dilek, Cakir, Ebru, Aiacaciogiu, Ahmet, Varol, Umut, Ahmet Alacacioglu, Unlu, Ause Gulden Diniz, ALTUN, ZEKİYE SULTAN, Butun, Osman, Osman Butun, Ebru Cakır, Zekiye Sultan Altun, AKTAŞ, SAFİYE, Dilek, Fatma Husniye, Umut Varol, Ayse Gulden Diniz Unlu, Isil Somali   +19 more
core   +1 more source

Correlation of prognostic factors with MRI findings in malignant breast lesions

The Egyptian Journal of Radiology and Nuclear Medicine, 2020
Background Magnetic resonance imaging (MRI) of the breast represents the most sensitive imaging modality in the detection of breast cancer, with a reported sensitivity between 94 and 100%.
Kerim Temiz, Pelin Seher Oztekin, Sema Hucumenoglu, Enver Necip Koseoglu, Pinar Nercis Kosar   +4 more
doaj   +1 more source

Prognostic Factors for Vulvar Cancer

Acta clinica Croatica, 2021
The aim of this retrospective study was to show the effect of clinical, pathologic, cytologic and therapeutic prognostic factors on treatment outcome and survival of patients suffering from vulvar cancer and to determine prognostic significance of each of the individual factors, their mutual significance and impact on survival.
Miljanović-Špika, Ivana, Drežnjak Madunić, Maja, Topolovec, Zlatko, Kujadin Kenjereš, Dajana, Vidosavljević, Domagoj   +4 more
openaire   +4 more sources

Comparative Drug Response Profiling in Neuroblastoma Cell Lines and Patient‐Derived Tumor Organoids

Pediatric Blood &Cancer, EarlyView.
ABSTRACT High‐risk neuroblastoma remains a leading cause of pediatric cancer mortality, and improved preclinical models are needed to guide therapeutic developments. We screened seven high‐risk neuroblastoma cell lines and three patient‐derived tumor organoids with 528 compounds alongside bone marrow controls, and compared them with external datasets ...
Krzysztof Wierbiłowicz, Se Whee Sammy Park, Aironas Los, Ernest Liu, Nona Struyf, Tom Erkers, Sören Lehmann, Jan J. Molenaar, Jakob Stenman, Olli Kallioniemi, Päivi Östling, Brinton Seashore‐Ludlow, Kasper Karlsson   +12 more
wiley   +1 more source

Sequential Allocation and Balancing Prognostic Factors in a Psychiatric Clinical Trial [PDF]

, 2008
In controlled clinical trials, each of several prognostic factors should be balanced across the trial arms. Traditional restricted randomization may be proved inadequate especially with small sample sizes.
Carlos A. B. Pereira, Basilio B. Pereira, Victor Fossaluza, Juliana B. Diniz, Euripedes C. Miguel   +4 more
core  

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma [PDF]

, 2010
Background: The enhancer of zeste homolog 2 (EZH2) gene exerts oncogene-like activities and its (over)expression has been linked to several human malignancies. Here, we studied a possible association between EZH2 expression and prognosis in patients with
Johannes Hüsing, Wagener, Nina, Hüsing Johannes, Karin Hoppe-Seyler, Hoppe-Seyler Felix, Peter Schirmacher, Hoppe-Seyler, Karin, Pfitzenmaier, Jesco, Macher-Göppinger, Stephan, Jesco Pfitzenmaier, Hohenfellner, Markus, Hüsing, Johannes, Haferkamp, Axel, Haferkamp Axel, Stephan Macher-Goeppinger, Maria Pritsch, Wagener Nina, Pritsch Maria, Axel Haferkamp, Schirmacher Peter, Nina Wagener, Hoppe-Seyler Karin, Hohenfellner Markus, Felix Hoppe-Seyler, Hoppe-Seyler, Felix, Pfitzenmaier Jesco, Macher-Goeppinger Stephan, Markus Hohenfellner, Pritsch, Maria, Schirmacher, Peter   +29 more
core   +2 more sources

Progression of disease within 24 months (POD24) in multiple myeloma implicates poor prognosis and limitations of current prediction models for POD24

Scientific Reports
Multiple myeloma (MM) is a common hematological malignancy, and its prognostic factors have been extensively studied. Progression of disease within 24 months (POD24) suggests a poor prognosis in many malignancies, but is rarely mentioned in MM.
Yongqin Cao, Yingying Gong, Qingqing Wang, Jun Xia, Xin Zhou, Chao Sun   +5 more
doaj   +1 more source

Impact of Radiation Therapy on Physical and Psychosocial Health of Adolescents and Young Adults: A Joint Report From the Children's Oncology Group AYA and Radiation Oncology Committees

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Rates of cancer among adolescents and young adults (AYA), age 15–39 years, are increasing. Consequently, radiation oncologists are treating more AYAs who have diagnoses spanning both pediatric and adult practices. Compared to pediatric and older adult patients, AYAs face a unique set of challenges.
Hesham Elhalawani, Rachel K. Peterson, Avani D. Rao, Laurie J. McKenzie, Ahmed Magdy Elmotayam, Leslie Chang, Michael Roth, Susan L. McGovern   +7 more
wiley   +1 more source

PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA [PDF]

Mediterranean Journal of Hematology and Infectious Diseases, 2014
Hodgkin lymphoma (HL) is among the neoplastic diseases that has the best long-term outcome after cytotoxic treatment. Cure rates approach 80-90%, however, 15-20% of patients will be resistant to therapy (primary refractory) or relapse after treatment.
Cuccaro, Annarosa, Bartolomei, Francesca, Cupelli, Elisa, Galli, Eugenio, Giachelia, Manuela, Hohaus, Stefan   +5 more
openaire   +3 more sources

Social Functioning Within the First Years After Pediatric Brain Tumor Diagnosis and the Relationship With Family Psychosocial Risk

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivors of pediatric brain tumors (PBTs) can experience long‐term social difficulties, impacting quality of life. Beyond medical and environmental factors, family psychosocial risk may play a role in social outcomes by shaping the caregiving environment and may provide intervention options.
Renske H. Houben, Marisa H. Huisman, Martha A. Grootenhuis, Femke K. Aarsen, Marita Partanen   +4 more
wiley   +1 more source